Apoptosis of T-47D cells induced by cinobufacini via a caspase-3-dependent manner

Abstract

To investigate the mechanism of the anti-tumor activity of cinobufacini on the breast cancer cell line T-47D, the inhibitory effect of cinobufacini on the proliferation of T-47D was detected via MTT assay and the morphological changes of T-47D and HBL-100 cells caused by cinobufacini were observed with an inverted microscope. Cell apoptosis and cell cycle stages were detected by flow cytometry analysis. The effects of cinobufacini on the expression of active-form and pro-form of caspase-3 were assessed by Western blot analysis. Cinobufacini dramatically inhibited T-47D proliferation in a dose- and time-dependent manner. We found that more than 20% of T-47D cells were killed after treatment with 20 mg/mL cinobufacini for 24 h in vitro. After 6 d of treatment with 20 mg/mL cinobufacini, the cell survival rate decreased by more than 40%. Flow cytometric analysis demonstrated that cinobufacini induced significant apoptosis and changes of the cell cycle distribution of T-47D cells. We used breast cell line HBL-100 as the control, the above experiments except cell cycle analysis showed that cinobufacini more obviously induced the apoptosis of T-47D cells than that of HBL-100 cells. Western blot analysis confirmed the protein expression of active caspase-3 increased with increasing the dose of cinobufacini. These results indicate that cinobufacini induces the apoptosis of T-47D cells via the up-regulation of caspase-3.

Keywords

Breast cancer cell / Cinobufacini / Apoptosis / Caspase-3

References

[1] Huang Y Z, Chen W Q, Wu C X, Zheng S R, Chen J G, Cheng L P, Wang N, Zhang S W, Zheng Y. Tumor, 2012, 8: 605.

[2] Siegel R, Naishadham D, Jemal A. CA Cancer J. Clin., 2012, 62(1): 10.

[3] Robert W, Carlson D, Craig A, Benjamin O A. National Comprehensive Cancer Network, 2012.

[4] Zhu X Y, Meng Z Q, Chen Z, Yu P Z, Ge Y Q, Liu L M. Chemistry Online, 2007, 10: 797.

[5] Zhang Y, Tang X, Liu X L, Li F, Lin X. Analytica Chimica Acta, 2008, 610(2): 224.

[6] Zhang Z Y, Zhang C H, Wang C W, Zhu J Q, Zhu Z H, Huang D Q. Traditional Chinese Drugs Research and Clinical Pharmacology, 1999, 15(5): 28.

[7] Qi F, Inagaki Y, Gao B, Cui X Y, Xu H L, Kokudo N, Li A Y, Tang W. Cancer Sci., 2011, 102(5): 951.

[8] Qi F, Lia A, Zhao L, Xu H L, Inagaki Y, Wang D L, Cui X Y, Gao B, Kokudo N, Nakata M, Tang W. J. Ethnopharmacol, 2010, 128(3): 654.

[9] Ma L, Song B, Jin H, Pi J, Liu L, Jiang J H, Cai J Y. Bioorg. Med. Chem. Lett., 2012, 22(3): 1459.

[10] Yin W J, Liu G Y, Di G H, Wu J, Lu J S, Han Q X, Shen Z Y, Liu L M, Shao Z M. Tumor, 2009, 29(7): 641.

[11] Lee D Y, Yasuda M, Yamamoto T, Yoshida T, Kuroiwa Y. Life Sci., 1997, 60(2): 127.

[12] Sheng X S, Xui L J. Journal of Practical Oncology, 2007, 1: 32.

[13] Piao B G, Li X, Sun L L, Kan S F, Liu L, Huang H Y, Yang G H, Wang Y H, Sun J H, Piao Y F, Jin N Y. Chem. Res. Chinese Universities, 2011, 27(3): 455.

[14] Xie R F, Li Z C, Gao B, Shi Z N, Zhou X. J. Ethnopharmacol, 2012, 141(2): 692.

[15] Yin J Q, Wen L, Wu L C, Gao Z H, Huang G, Wang J, Zou C Y, Tan P X, Yong B C, Jia Q, Shen J N. Toxicol. Lett., 2013, 218(2): 129.

[16] Alan G P, Reiner U J. Cell Death and Differentiation, 1999, 6: 99.

[17] Elore S. Toxicologic Pathology, 2007, 35: 495.

[18] Nagata S. Cell Press, 1997, 88: 355.

[19] Li Y, Shen J T, Gao C, Li Q, Jin Y H. Chem. Res. Chinese Universities, 2010, 26(5): 792.

[20] Yu C H, Kan S F, Pu H F, Jea C E, Wang P S. Cancer Sci., 2008, 99(12): 2467.

[21] Sun Y, Lu X X, Liang X M, Cui X N. Chinese-German Journal of Clinical Oncology, 2011, 10(1): 27.

[22] Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Jpn. J. Cancer Res., 1994, 85(6): 645.

[23] Watahe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. Biol. Chem., 1996, 271(24): 14067.

[24] Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Blood Cells Mol. Dis., 2002, 28: 160.